Close Menu


The firm anticipates submitting its Acuitas AMR Gene Panel u5.47 for urinary tract infections and antibiotic resistance to US regulators by early next year.

OpGen will provide genetic panels and analysis software to the DOH's Wadsworth Center while Merck's Ilúm will provide health data aggregation and insights. 

The firm's lab services and product revenues fell year over year, but collaboration revenues increased during Q2.

A brief recap of Genetics/Genomics news the week of Jun 15, 2018: Epistem, Exosome Diagnostics, Luminex, Bluebee, Abomics, and OpGen

The revenue growth was driven by an increase in collaboration revenues, which offset declines in product sales and lab services revenues.

This week's news about SeraCare Life Sciences, Human Longevity Clinical Labs, CareDx, Interpace Diagnostics, Boston Scientific, OpGen,  and MDxHealth's SelectMDx.

The firm reported revenues of $990,912 compared to $1.0 million a year ago, as product sales dropped 23 percent and collaboration revenues rose 157 percent

The collaborative study includes testing urine samples from patients who have an increased risk for complicated urinary tract infections.

OpGen recently launched the first Acuitas test, which is designed to detect the most common bacterial causes of complicated urinary tract infections.

OpGen said it will use the net proceeds for R&D, including the continued development of its Acuitas AMR gene panels.


Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.